Welichem Receives Additional Contribution from NRC-IRAP to Continue Research on its Anticancer Compound, WBI-2100

BURNABY, BC, March 13 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI - News), is pleased to announce that the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) has recently provided an increase to the Company's original contribution agreement of up to $118,000. The contribution will assist Welichem with research and development on its unique oncology drug candidate, WBI-2100. This contribution agreement will allow the Company to have up to a total of $460,000 towards the development of this particular R&D project.

NRC-IRAP works with small- and medium-sized Canadian enterprises, providing advisory services and potential funding to clients to help them develop innovative R&D projects.

Preliminary studies on WBI-2100 have indicated significant therapeutic potential against solid tumours concurrent with increasing the number of neutrophils (a type of white blood cell an increased number of which enhances immune system function). Additional positive tests could lead to a full drug development program for this compound's anti-cancer and anti-neutropenia (a condition with reduced number of neutrophils usually caused by cancer chemotherapy drugs) properties.

About Welichem Biotech Inc.

Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer.

ON BEHALF OF THE BOARD
York Yingping Guo
President and Chief Executive Officer

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements.

For further information

York Yingping Guo, President and Chief Executive Officer, Tel.: (604) 432-1703, Email: yorkguo@welichem.com

Yan Chen, Business Development Manager, Tel.: (604) 432-1703, Email: investors@welichem.com

--------------------------------------------------------------------------------

Source: Welichem Biotech Inc.